home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Monster Media 1994 #2
/
Monster Media No. 2 (Monster Media)(1994).ISO
/
text
/
med9404c.zip
/
M9460966.TXT
< prev
next >
Wrap
Text File
|
1994-05-10
|
3KB
|
43 lines
Document 0966
DOCN M9460966
TI Is there any predictive factor of the clinical response to IL2 therapy
in metastatic malignant melanoma (Meeting abstract).
DT 9406
AU Soubrane C; Mouawad R; Ichen M; Suissa J; Vuillemin E; Borel C;
Benhammouda A; Weil M; Khayat D; Oncology Medical Lab., Salpetriere
Hosp., 75013 Paris, France
SO Fourth International Congress on Anti-cancer Chemotherapy. February 2-5,
1993, Paris, France, p. 99, 1993.. Unique Identifier : AIDSLINE
ICDB/94697771
AB Immunological parameters following chemo-immunotherapy combination were
studied in 31 patients with metastatic malignant melanoma. They received
cisplatin (100 mg/m2) at day 1 and 28, r-interleukin-2 (IL2, Eurocetus)
in continuous infusion from day 3-6, 17-21, 31-34 and 45-49. Alpha
interferon (Roche) was given sc three times weekly. No significant
change in CD4/CD8 ratio both at onset or during treatment was observed
between responder (n = 19) and nonresponder (n = 11) patients. Regarding
IL2 receptor study, the percentage of cells expressing TAC (p55)
receptor did not change either between healthy volunteers (n = 20) and
patients before any therapy or between responder and nonresponder
patients. Concerning soluble IL2R shedding before any therapy, we
observed a significant increase (p = 0.001) in patients (79 +/- 40 PM)
compared to healthy donors (30.6 +/- 15 PM) but no significant variation
was seen between responder and nonresponder patients. In contrast,
during the treatment, the soluble IL2R ratio increased in both groups
but, interestingly a significant difference was found between responder
and nonresponder patients from day 7 (p less than 0.05) to day 21 (p
less than 0.01) suggesting that the cells from nonresponder may be
slower in becoming stimulated. It is the most striking point of our
study since sIL2R might be an early predictive factor of the clinical
response as obtained by logistic regression (p = 0.0063).Therefore
patients with a soluble IL2R level greater than 250 PM have 12-fold more
chances to present a clinical response.
DE CD4-CD8 Ratio Cisplatin/*ADMINISTRATION & DOSAGE Human
Interferon-alpha/THERAPEUTIC USE Interleukin-2/*ADMINISTRATION & DOSAGE
Melanoma/DRUG THERAPY/METABOLISM/PATHOLOGY/*THERAPY Receptors,
Interleukin-2/METABOLISM MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).